

Registered Office:

815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA). **Ph.**: +91-265-2991021 / 2991022

Email: admin@pardrugs.com

CIN No.: L24117GJ1999PLC035512

www.pardrugs.com

PAR/CS/NSE/2022-23/30

To, Date: 09/08/2022

The Manager

Listing department,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G,

Bandra Kurla Complex, Bandra (E),

Mumbai- 400 051

Maharashtra

Symbol - PAR, ISIN: INE04LG01015

Subject: Investors Presentation

Ref.: Regulation 30 read with Schedule III of SEBI (Listing Obligations And

Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to above captioned subject and pursuant Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby attached our latest Investors Presentation.

You are requested to kindly take note on your record.

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Mr. Falgun V. Savani)

Managing Director

DIN: 00198236 Encl: As above





Q1-FY23 Earnings Presentation




Company Overview






- Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs.
- The Company today manufactures 25 different products and all the requisite grades as available in the market. The product portfolio presently comprises of 15 APIs and 10 Fine Chemicals which are marketed domestically and exported.
- Currently, the company owns and operates a manufacturing facility at Bhavnagar in Gujarat with an annual capacity of 9,700 MT.
- The company is the largest manufacturer of Magnesium Hydroxide, Sucralfate and Magnesium Trisilicate in India.
- Company's key customers include Essential Drugs Company Ltd., Pfizer Ltd., United Phosphorus Ltd., Cipla Ltd., etc.
- PDCL exports its products to approximately 16 countries, including Germany, the United Kingdom, Bangladesh, Iran, and U.A.E etc.
- APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

Operational Revenues (INR Mn)



Business Mix (Q1-FY23)



Key Strengths





Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported.



Global Presence: The Company is operating both in domestic and export markets. The export products are to approximately 16 countries, including Germany, United Kingdom, Bangladesh, Iran, and U.A.E, Indonesia, Japan, South Korea, etc.



Experienced Promoters: Led by qualified and experienced Promoters and key managerial personnel, who we believe have extensive knowledge and understanding of the APIs business environment and have the expertise and vision to organically scale up the business.



Robust Chemistry Capabilities: A research driven Company with R&D efforts focused on developing processes and achieving process improvements and production cost efficiencies.



Diversified Customer base: Catering to more than 241 customers through dealers/agents worldwide.



Established Sales and distribution network: Comprising of more than 40 dealers and distribution network is spread globally comprising of 13 agents.



Cash Rich Company: The company is a net debt free and generates free cash flow. They plans it expansions through internal accruals.



Q1-FY23 Financial & Operational Highlights



Q1-FY23 Financial Highlights

Revenue	EBITDA	EBITDA Margin
INR 235 Mn	INR 37 Mn	15.74%
PAT	PAT Margin	Diluted EPS
INR 23 Mn	9.79%	INR 1.86

Operational Highlights

- For Q1-FY23, sales grew by around 43% YOY, driven by a sales growth in the domestic market of 35% and in the export market of 74% YOY.
- In our sales product mix, there has been an increase in the sale of higher profit margin items without compromising sales of lower profit margin items.
- Raw material costs increased 37% to 46% of our sales and prices of our main raw materials increased by 2-3 times on a YOY basis.
- The price hike of the raw materials was successfully passed on to the end consumers.
- In order to enhance the quality of the products, the company has revamped the existing old plant pertaining to new requirements without any major cash outflow.
- In the current year, the company has also signed a non disclosure agreement with M/s. Kyova Chemicals, Japan.



Quarterly Financial Performance (IND-AS)



Income Statement (INR Mn)	Q1-FY23	Q1-FY22	Y-o-Y	Q4-FY22	Q-o-Q
Income from Operations	235	165	42.4%	221	6.3%
Total Expenses	198	124	59.7%	176	12.5%
EBITDA	37	41	(9.8)%	45	(17.8)%
EBITDA Margins (%)	15.74%	24.85%	(911)Bps	20.36%	(462)Bps
Finance Cost	1	-	NA	1	NA
Depreciation	7	8	(12.5)%	9	(22.2)%
Other Income	2	-	NA	1	NA
Profit before Extraordinary Items	31	33	(6.1)%	36	(13.9)%
Profit Before Tax	31	33	(6.1)%	36	(13.9)%
Tax	8	9	(11.1)%	12	(33.3)%
Profit after tax	23	24	(4.2)%	24	(4.2)%
PAT Margins (%)	9.79%	14.55%	(476)Bps	10.86%	(107)Bps
Other Comprehensive Income	-	-	NA	-	NA
Total Comprehensive Income	23	24	(4.2)%	24	(4.2)%
Diluted EPS (INR)	1.86	2.00	(7.0)%	1.97	(5.6)%

Historical Income statement



Income Statement (INR Mn)	FY20	FY21	FY22	Q1-FY23
Income from Operations	558	608	751	235
Total Expenses	464	447	588	198
EBITDA	94	161	163	37
EBITDA Margins (%)	16.85%	26.48%	21.70%	15.74%
Finance Cost	8	7	5	1
Depreciation	27	28	33	7
Other Income	1	2	2	2
Profit before Extra Ordinary Items	60	128	127	31
Extraordinary items	-	(19)	-	-
Profit Before Tax	60	147	127	31
Tax	12	31	35	8
Profit after tax	48	116	92	23
PAT Margins (%)	8.60%	19.08%	12.25%	9.79%
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	48	116	92	23
Diluted EPS (INR)	7.75	18.87	7.49	1.86


Balance Sheet





EQUITIES & LIABILITIES (INR Mn)	FY20	FY21	FY22	ASSETS (INR Mn)	FY20	FY21	FY22
Shareholder Funds	406	522	599	Non Current Assets	359	352	351
(A) Equity Share Capital	61	61	123	(A) Fixed Assets	-	-	
(B) Reserves & Surplus	345	461	476	(i) Tangible Assets	344	299	341
				(ii) Capital work-in-progress	7	45	2
Non-current Liabilities	87	82	39	(B) Non Current Investments	1	-	-
(A) Long Term borrowings	46	44	-	(C) Other Non Current Assets	7	8	8
(B) Deferred Tax Liabilities (net)	37	34	35				
(C) Long term Provisions	4	4	4				
Current Liabilities	108	160	149	Current Assets	242	412	436
(A) Short term borrowings	-	32	-	(A) Inventories	29	30	47
(B) Trade Payables	62	67	107	(B) Trade Receivables	124	125	185
(C) Other Current Liabilities	27	25	8	(C) Cash & cash equivalents	74	212	163
(D) Short term Provisions	19	36	34	(D) Short Term Loans & Advances	6	-	-
				(E) Other Current Assets	9	45	41
GRAND TOTAL - EQUITIES & LIABILITES	601	764	787	GRAND TOTAL – ASSETS	601	764	787

Financial Highlights











Net Worth (INR Mn)






Net Debt to Equity Ratio (x)





Capital Market Highlights





Price Data (30 th June, 2022)	INR
Face Value	10
Market Price	143.5
52 Week High/Low	310.6/87
Market Cap (Mn)	1,765
Equity Shares Outstanding (Mn)	12.3
1 Year Avg Trading Volume ('000)	30.96





Disclaimer



Par Drugs and Chemicals Limited:

The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied. whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from, this Presentation is expressly excluded. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence. investigation etc may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forwardlooking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal Valorem Advisors

Tel: +91-22-4903-9500

Email: pardrugs@valoremadvisors.com

